Chen Yu, Li Qing, Du Liya, Du Zhuowen, Zhou Yixi, Huang Yanru, Zhang Jian, Wang Wenbo, Zhang Lutan, Xie Jieqiong, Xu Chao, Ge Yunsheng, Yao Xingmei, Zhou Yulin
Department of Central Laboratory, Fujian Key Clinical Specialty of Laboratory Medicine, Department of Obstetrics and Gynecology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
United Diagnostic and Research Center for Clinical Genetics, Women and Children's Hospital, School of Medicine and School of Public Health, Xiamen University, Xiamen, Fujian, China.
Front Microbiol. 2025 Apr 4;16:1546166. doi: 10.3389/fmicb.2025.1546166. eCollection 2025.
Human papillomavirus (HPV) vaccination is expected to reduce the burden of cervical cancer and other HPV-related diseases. However, if competition exists among HPV types, type replacement may occur following the reduction of vaccine-targeted types. Here, we conducted the study to explore natural HPV type competition in unvaccinated women.
HPV DNA test results from cervical samples collected between January 2013 and July 2023 at Xiamen University's Women and Children's Hospital were analyzed. In cross-sectional study, first-visit HPV genotyping results were used, and logistic regression model was constructed to evaluate interactions between vaccine-targeted and other HPV types. In cohort of women with multiple visits, the risk of acquiring other HPV types was compared between women infected with vaccine-targeted types and those HPV-negative using Cox proportional hazards model.
Among 159,049 women, 19.8% tested HPV-positive, with 5.1% having multiple types. Significant negative associations were observed between HPV-6 and HPV-72 (OR: < 0.01; 95%CI: < 0.01-0.03), HPV-18 and HPV-72 (OR: < 0.01; 95%CI: < 0.01-0.02), HPV-31 and HPV-83 (OR: < 0.01; 95%CI: < 0.01-0.55), HPV-33 and HPV-26 (OR: < 0.01; 95%CI: < 0.01-0.81), HPV-45 and HPV-55 (OR: < 0.01; 95%CI: < 0.01- < 0.01), HPV-56 and HPV-26 (OR: < 0.01; 95%CI: < 0.01-0.09), as well as HPV-59 and HPV-69 (OR: < 0.01; 95%CI: < 0.01-0.68), suggesting potential type competition. However, no type competition pair was found in the cohort study. Conversely, women with vaccine-targeted types had a higher risk of acquiring other types (HR > 1.0).
Our findings suggested that HPV-6 and HPV-72, HPV-18 and HPV-72, HPV-31 and HPV-83, HPV-33 and HPV-26, HPV-45 and HPV-55, HPV-56 and HPV-26, HPV-59 and HPV-69 were potential type competition pairs.
人乳头瘤病毒(HPV)疫苗接种有望减轻宫颈癌和其他HPV相关疾病的负担。然而,如果HPV各型之间存在竞争,那么在疫苗靶向型减少之后可能会发生型别替代。在此,我们开展了这项研究以探索未接种疫苗女性中HPV自然型别竞争情况。
分析了2013年1月至2023年7月在厦门大学附属妇女儿童医院收集的宫颈样本的HPV DNA检测结果。在横断面研究中,使用首次就诊时的HPV基因分型结果,并构建逻辑回归模型来评估疫苗靶向型和其他HPV型之间的相互作用。在多次就诊的女性队列中,使用Cox比例风险模型比较感染疫苗靶向型的女性和HPV阴性女性感染其他HPV型的风险。
在159,049名女性中,19.8%的检测结果为HPV阳性,其中5.1%感染了多种型别。观察到HPV-6与HPV-72(比值比:<0.01;95%置信区间:<0.01-0.03)、HPV-18与HPV-72(比值比:<0.01;95%置信区间:<0.01-0.02)、HPV-31与HPV-83(比值比:<0.01;95%置信区间:<0.01-0.55)、HPV-33与HPV-26(比值比:<0.01;95%置信区间:<0.01-0.81)、HPV-45与HPV-55(比值比:<0.01;95%置信区间:<0.01-<0.0!)、HPV-56与HPV-26(比值比:<0.01;95%置信区间:<0.01-0.09)以及HPV-59与HPV-69(比值比:<0.01;95%置信区间:<0.01-0.68)之间存在显著负相关,提示存在潜在的型别竞争。然而,在队列研究中未发现型别竞争对。相反,感染疫苗靶向型的女性感染其他型别的风险更高(风险比>1.0)。
我们的研究结果表明,HPV-6与HPV-72、HPV-18与HPV-72、HPV-31与HPV-83、HPV-33与HPV-26、HPV-45与HPV-55、HPV-56与HPV-26、HPV-59与HPV-69是潜在的型别竞争对。